FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022161880> ?p ?o ?g. }

• W2022161880 endingPage "e43409" @default.
• W2022161880 startingPage "e43409" @default.
• W2022161880 abstract "Targeted therapies, associated with standard chemotherapies, have improved breast cancer care. However, primary and acquired resistances are frequently observed and the development of new concepts is needed. High-throughput approaches to identify new active and safe molecules with or without an a priori are currently developed. Also, repositioning already-approved drugs in cancer therapy is of growing interest. The thiomorpholine hydroxamate compound TMI-1 has been previously designed to inhibit metalloproteinase activity for the treatment of rheumatoid arthritis. We present here the repositioning of TMI-1 drug in breast cancer.We tested the effect of TMI-1 on luminal, basal and ERBB2-overexpressing breast tumor cell lines and on MMTV-ERBB2/neu tumor evolution. We measured the effects on i) cell survival, ii) cell cycle, iii) extrinsic and intrinsic apoptotic pathways, iv) association with doxorubicin, docetaxel and lapatinib, v) cancer stem cells compartment. In contrast with conventional cytotoxic drugs, TMI-1 was highly selective for tumor cells and cancer stem cells at submicromolar range. All non-malignant cells tested were resistant even at high concentration. TMI-1 was active on triple negative (TN) and ERBB2-overexpressing breast tumor cell lines, and was also highly efficient on human and murine primary ERBB2-overexpressing cells. Treatment of transgenic MMTV-ERBB2/neu mice with 100 mg/kg/day TMI-1 alone induced tumor apoptosis, inhibiting mammary gland tumor occurrence and development. No adverse effects were noticed during the treatment. This compound had a strong synergistic effect in association with docetaxel, doxorubicin and lapatinib. We showed that TMI-1 mediates its selective effects by caspase-dependent apoptosis. TMI-1 was efficient in 34/40 tumor cell lines of various origins (ED50: 0.6 µM to 12.5 µM).This is the first demonstration of the tumor selective cytotoxic action of a thiomorpholin hydroxamate compound. TMI-1 is a novel repositionable drug not only for the treatment of adverse prognosis breast cancers but also for other neoplasms." @default.
• W2022161880 created "2016-06-24" @default.
• W2022161880 creator A5009364522 @default.
• W2022161880 creator A5033716671 @default.
• W2022161880 creator A5039946471 @default.
• W2022161880 creator A5051980875 @default.
• W2022161880 creator A5063779337 @default.
• W2022161880 creator A5064649152 @default.
• W2022161880 creator A5067040385 @default.
• W2022161880 creator A5072157551 @default.
• W2022161880 creator A5081680353 @default.
• W2022161880 creator A5090878677 @default.
• W2022161880 date "2012-09-18" @default.
• W2022161880 modified "2023-10-18" @default.
• W2022161880 title "Tumor Selective Cytotoxic Action of a Thiomorpholin Hydroxamate Inhibitor (TMI-1) in Breast Cancer" @default.
• W2022161880 cites W1754585763 @default.
• W2022161880 cites W1910707858 @default.
• W2022161880 cites W1980389722 @default.
• W2022161880 cites W1983592978 @default.
• W2022161880 cites W1984483611 @default.
• W2022161880 cites W2009477654 @default.
• W2022161880 cites W2010462123 @default.
• W2022161880 cites W2013006388 @default.
• W2022161880 cites W2023316892 @default.
• W2022161880 cites W2023826235 @default.
• W2022161880 cites W2029431941 @default.
• W2022161880 cites W2033341544 @default.
• W2022161880 cites W2045732854 @default.
• W2022161880 cites W2073184188 @default.
• W2022161880 cites W2074152898 @default.
• W2022161880 cites W2077945404 @default.
• W2022161880 cites W2078401315 @default.
• W2022161880 cites W2090685720 @default.
• W2022161880 cites W2091952500 @default.
• W2022161880 cites W2092890170 @default.
• W2022161880 cites W2098536205 @default.
• W2022161880 cites W2102215248 @default.
• W2022161880 cites W2102362155 @default.
• W2022161880 cites W2105504936 @default.
• W2022161880 cites W2106195342 @default.
• W2022161880 cites W2115358608 @default.
• W2022161880 cites W2116561160 @default.
• W2022161880 cites W2117237148 @default.
• W2022161880 cites W2117476815 @default.
• W2022161880 cites W2125747634 @default.
• W2022161880 cites W2127617517 @default.
• W2022161880 cites W2131994307 @default.
• W2022161880 cites W2141436693 @default.
• W2022161880 cites W2145341466 @default.
• W2022161880 cites W2146413251 @default.
• W2022161880 cites W2158699436 @default.
• W2022161880 cites W2162647235 @default.
• W2022161880 cites W2163857222 @default.
• W2022161880 cites W2166779240 @default.
• W2022161880 cites W2170816578 @default.
• W2022161880 cites W66301014 @default.
• W2022161880 doi "https://doi.org/10.1371/journal.pone.0043409" @default.
• W2022161880 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3445597" @default.
• W2022161880 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23028451" @default.
• W2022161880 hasPublicationYear "2012" @default.
• W2022161880 type Work @default.
• W2022161880 sameAs 2022161880 @default.
• W2022161880 citedByCount "3" @default.
• W2022161880 countsByYear W20221618802014 @default.
• W2022161880 countsByYear W20221618802021 @default.
• W2022161880 countsByYear W20221618802022 @default.
• W2022161880 crossrefType "journal-article" @default.
• W2022161880 hasAuthorship W2022161880A5009364522 @default.
• W2022161880 hasAuthorship W2022161880A5033716671 @default.
• W2022161880 hasAuthorship W2022161880A5039946471 @default.
• W2022161880 hasAuthorship W2022161880A5051980875 @default.
• W2022161880 hasAuthorship W2022161880A5063779337 @default.
• W2022161880 hasAuthorship W2022161880A5064649152 @default.
• W2022161880 hasAuthorship W2022161880A5067040385 @default.
• W2022161880 hasAuthorship W2022161880A5072157551 @default.
• W2022161880 hasAuthorship W2022161880A5081680353 @default.
• W2022161880 hasAuthorship W2022161880A5090878677 @default.
• W2022161880 hasBestOaLocation W20221618801 @default.
• W2022161880 hasConcept C121608353 @default.
• W2022161880 hasConcept C126322002 @default.
• W2022161880 hasConcept C154317977 @default.
• W2022161880 hasConcept C190283241 @default.
• W2022161880 hasConcept C202751555 @default.
• W2022161880 hasConcept C2776187077 @default.
• W2022161880 hasConcept C2776694085 @default.
• W2022161880 hasConcept C2777329042 @default.
• W2022161880 hasConcept C2779786085 @default.
• W2022161880 hasConcept C2781190966 @default.
• W2022161880 hasConcept C2781303535 @default.
• W2022161880 hasConcept C502942594 @default.
• W2022161880 hasConcept C530470458 @default.
• W2022161880 hasConcept C55427017 @default.
• W2022161880 hasConcept C55493867 @default.
• W2022161880 hasConcept C71924100 @default.
• W2022161880 hasConcept C86803240 @default.
• W2022161880 hasConcept C96232424 @default.
• W2022161880 hasConcept C98274493 @default.
• W2022161880 hasConceptScore W2022161880C121608353 @default.

• next